

October 21, 2019

Dear Fellow OncoSec Shareholders,

On Thursday, October 10, 2019, we announced an important strategic transaction with China Grand Pharmaceutical and Healthcare Holdings (CGP) and its U.S. affiliate, Sirtex Medical Holdings, Inc. (Sirtex) that we believe is in the best interest for all OncoSec shareholders¹. In summary, upon approval of our shareholders, this transaction would bring a \$30 million cash infusion at a premium to our recent price per share and fund both of our ongoing KEYNOTE clinical trials of TAVO[™] in combination with Merck's KEYTRUDA[®] to completion.

Over the next several weeks, we will be actively communicating with you regarding the shareholder value this strategic transaction creates.

While we believe there are numerous shareholder positives, we wish to begin by calling to your attention several very important benefits of this strategic transaction:

- Should CGP seek to offer to acquire the outstanding shares of OncoSec within the 12 months following the closing of the transaction, the offer price for the outstanding shares of OncoSec must be the greater of \$4.50 per share or 110% of the last closing stock price of the common stock on the date prior to making such an offer. **This is not a right to acquire the outstanding shares of OncoSec for \$4.50 or higher, but rather the ability to offer to do so.** The OncoSec Board is not obligated to accept any such offer and would evaluate it based on the best interest of OncoSec shareholders at that time. In addition, following the initial transaction, CGP and Sirtex will not have a majority of the Board of Directors and would be entitled to a total of only three of nine seats on the OncoSec Board of Directors as a result of the transaction.
- This establishes a **very favorable floor, not a ceiling**, on a potential acquisition price at a significant premium from our current valuation. For example, should the stock be trading above \$4.50 and CGP wishes to offer to acquire the outstanding shares, CGP would be required to offer at least 110% of the stock price at that time (i.e., if the stock is trading at \$7.00, CGP would need to offer at least \$7.70). Again, the OncoSec Board of Directors is not obligated to accept any such offer and would evaluate it based on the best interests of OncoSec shareholders.

For this transaction to be approved, an affirmative vote from a majority of OncoSec's shareholders is required. Please note, because of the nature of the proposed transaction, your broker cannot vote your shares for you. Therefore, in order for your vote to count, you will need to vote yourself.

¹ Details of the transaction can be found in OncoSec's filings with the U.S. Securities and Exchange Commission.

To this end, you will receive a Proxy Statement seeking your “YES” vote regarding the strategic investment by CGP and Sirtex. This Proxy will guide you through the voting process and how to vote using the WHITE proxy card that will be included.

We look forward to continuing to communicate to you the advantages we believe this strategic alliance would offer OncoSec and you as its shareholder.

Sincerely,



Daniel O'Connor
President, Director & CEO
OncoSec Medical Incorporated

More details of the agreement can be found in OncoSec’s filings with the U.S. Securities and Exchange Commission. This communication is being made in respect of the proposed transaction involving OncoSec Medical Incorporated (the “Company”), Grand Decade Developments Limited, a direct, wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited, and Sirtex Medical US Holding. In connection with the proposed transaction, the Company intends to file relevant materials with the Securities and Exchange Commission, including a proxy statement. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy statement and a proxy card to each stockholder of the Company entitled to vote at the special meeting relating to the proposed transaction. This communication is not a substitute for the proxy statement or any other document that the Company may file with the SEC or send to its stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, COMPANY STOCKHOLDERS ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSED TRANSACTION. The Company’s stockholders may obtain free copies of the proxy statement (when it becomes available) and other relevant documents filed with the SEC by the Company at the SEC’s web site (<http://www.sec.gov>). Free copies of the proxy statement, when available, and other filings made by the Company with the SEC also may be obtained from the Investor Relations section of the Company’s web site (www.oncosec.com) or by directing a request to the Company, Attn: Investor Relations, 24 North Main Street, Pennington, NJ 08534-2218.

The initial announcement of the strategic transaction can be accessed via OncoSec’s website at <https://ir.oncosec.com/press-releases/detail/2009/oncosec-announces-30-million-usd-strategic-investment-at-a>.